• HOME
  • FEATURE ARTICLE
  • SPOTLIGHT ARTICLE
  • CATEGORIES
    • MEDSPA
    • SKINCARE
    • PLASTIC SURGERY
    • HEALTH & WELLNESS
    • BEAUTY
    • CHIROPRACTIC
    • EDITIONS
  • EDITIONS
    • EDITIONS
November 16.2026
2 Minutes Read

Exploring TYK2 Inhibitors: A Game-Changer in Psoriasis Treatment Options

No Title

Understanding TYK2 Inhibitors: New Solutions for Psoriasis

Psoriasis patients now have a wider variety of treatment options, thanks to advancements in dermatological science. Dr. Mark Lebwohl, a leading dermatologist at the Icahn School of Medicine, has shared insights on the emerging class of TYK2 inhibitors, offering hope for improved skin health without invasive procedures.

What Are TYK2 Inhibitors?

TYK2 inhibitors are a new group of oral medications that target specific pathways in the immune system responsible for psoriasis. Unlike traditional treatments that often require injections, these pills present a non-invasive alternative that could help many patients feel more comfortable with their treatment plans. Deucravacitinib, known for showing superiority to apremilast, is leading this new category of psoriasis therapy.

Anticipated FDA Requirements for TYK2 Inhibitors

While the expected benefits of TYK2 inhibitors are promising, monitoring requirements are still being developed by the FDA. Dr. Lebwohl notes that although the agency has yet to define all necessary monitoring for these new agents, he anticipates research will focus on tuberculosis screening, liver health, and lipid levels. His experience with deucravacitinib has been positive, claiming no significant changes in blood parameters, which hints at less intensive monitoring compared to older therapies.

Choosing Between Oral and Injectable Options

In the current dermatology landscape, patients can choose between various oral and injectable options for treating psoriasis. Besides TYK2 inhibitors, Dr. Lebwohl highlights IL-17 and IL-23 blockers as effective alternatives, especially for severe cases. He emphasizes that the choice between these treatments often depends on the patient's preference for non-invasive methods versus urgency for rapid results.

Empowering Patients with More Choices

A significant takeaway from Dr. Lebwohl's insights is the empowerment that comes with having a variety of treatment options. Patients seeking to avoid injections now have oral alternatives that could fit into their lifestyles more seamlessly. Whether individuals prefer a speedy treatment with IL-17 blockers or the convenience of less frequent dosing with IL-23 blockers, the range of possibilities enhances patient autonomy and improves treatment satisfaction.

Conclusion: Take Charge of Your Psoriasis Journey

For those navigating the complexities of psoriasis, understanding the latest treatment innovations like TYK2 inhibitors can be transformative. With improved access to both oral and injectable therapies, there's hope for better skin health and empowering choices. Patients are encouraged to discuss these advancements with their healthcare providers to find the best path forward for their unique situations.

HEALTH & WELLNESS

1 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts
11.13.2026

Birthmarks and Their Hidden Warning Signs: What You Should Know

Update Understanding Birthmarks: The Signs You Shouldn't Ignore For many, birthmarks are just a part of unique skin characteristics, often simply seen as aesthetic attributes. However, as we dive deeper into skin health, it becomes imperative to understand that some birthmarks, particularly café-au-lait macules (CALMs), can be indicators of underlying conditions. The Importance of Neurofibromatosis Type 1 (NF1) Awareness Neurofibromatosis Type 1 (NF1) is a genetic condition that impacts how nerve cells form and operate, leading to various skin changes, including the development of multiple CALMs. Understanding this condition is critical, especially given that a diagnosis requires two or more of seven consensus criteria. It’s worth noting that CALMs only count towards the diagnostic criteria when there are larger lesions—specifically, for children, the size requirements differ before and after puberty. Why Knowing Your Skin Matters As individuals aged 45-75 increasingly invest in self-care and cosmetic procedures, being informed about the implications of skin changes is paramount. Urban dwellers often prioritize appearances; however, neglecting potential warning signs may lead to serious health consequences down the line. If you notice changes in your birthmarks, such as enlargement or color changes, it's time to consult a dermatologist. Early detection can be life-saving. Connecting Aesthetic Awareness to Health For the beauty-savvy consumer, understanding the significance of skin condition and health allows for more informed decisions, especially in the context of cosmetic treatments. Innovations such as injectable fillers and laser skin resurfacing techniques often address aesthetic concerns but can also interact with underlying skin health challenges. Techniques like micro-needling and chemical peels can rejuvenate skin texture but should be approached with a keen awareness of what lies beneath. Steps to Take for Your Skin Health Aside from regular dermatological check-ups, integrating preventative aesthetics into your routine can enhance both appearance and skin health. Technologies such as RF and laser therapies offer advanced solutions that not only address cosmetic concerns but also promote collagen production and improve skin elasticity. Finding treatments that align with your values of health and aesthetics will ensure a holistic approach to skincare. In conclusion, being proactive about skin changes is vital. Don’t dismiss the importance of any changes in birthmarks. Consult with skincare professionals and embrace current beauty trends responsibly while staying informed about their implications on overall skin health. Taking action through this new awareness could steer your beauty and health journey into a direction that not only elevates appearances but also safeguards your well-being for years to come.

11.11.2026

The Critical Balance: Understanding Pediatric Atopic Dermatitis Treatment Risks

Update Understanding Severe Pediatric Atopic Dermatitis: Risks of Undiagnosed Conditions As healthcare continues to evolve, the focus on treating chronic conditions such as pediatric atopic dermatitis (AD) becomes increasingly vital. Dr. Eingun James Song, a dermatologist at Frontier Dermatology, emphasizes the need to weigh treatment options carefully. His insights reveal that the conversation surrounding treatments cannot just focus on the risks associated with medications but should also address the potential dangers of under-treating severe diseases. Why Under-Treating Matters Dr. Song highlights that children suffering from severe AD are at a higher risk of developing additional complications, including asthma, food allergies, and even mood disorders like anxiety and depression. These comorbidities not only impact a child's immediate quality of life but can also have long-term repercussions on their overall health. The medical community advocates for a balanced approach that considers both the advantages of treatment, such as biologics like dupilumab, and the risk of leaving a serious condition unaddressed. Biologics: Not as Daunting as They May Seem When introducing biologic treatments to families, Dr. Song often draws parallels with established treatments like insulin and allergies shots. By comparing biologics to something familiar, he demystifies the perception of biologics being either solely a risk or a cure. Biologics are produced differently, yet they do not inherently carry more risk than traditional therapy options like steroids. The Need for Comprehensive Growth Studies Emerging data on growth impacts in children receiving dupilumab is gaining attention. However, Dr. Song cautions that the current findings stem from analyses lacking dedicated control beyond what is necessary to derive accurate conclusions. The urgency of conducting well-structured clinical trials to understand the relationship between treatment and growth is paramount, especially as new therapies gain approval. Exploring Benefits vs. Risks of Treatment Options Clinicians are tasked with not just understanding how a treatment works but also the broader implications on a child’s development and well-being. Dr. Song poses critical questions around whether benefits observed in treatments are due to the drug itself or its class. This exploration may lead to important revelations, including if all IL-13 inhibitors yield similar advantages, thus transforming treatment protocols. Impact on Families: A Call for Empowerment For middle and upper-class families deeply invested in their children's health and appearance, Dr. Song’s insights empower them to engage in informed discussions with their healthcare providers. By understanding the balance between treatment risks and efficacy, families can advocate for proactive strategies that enhance their children's overall quality of life. For those invested in skin health advancements, staying informed about new treatments and ongoing studies is crucial. Knowledge is not just power; it is a pathway to better health and wellness.

11.06.2026

ATTO-1310’s Phase 1b Study Shows Promise in Reducing Chronic Itch

Update Breaking New Ground: ATTO-1310's Promising ResultsIn an exciting development for those suffering from chronic pruritus (CP) and high-itch atopic dermatitis (AD), Attovia Therapeutics recently announced the positive topline results from its phase 1b study of ATTO-1310. This innovative therapy, targeting interleukin 31 (IL-31)—a key player in itch signaling—has shown significant promise in reducing itch for patients battling these challenging conditions.The study enrolled 52 participants, half with CP and half with high-itch AD, across 17 sites in the US and Canada. Remarkably, after 12 weeks, those receiving a single subcutaneous dose of ATTO-1310 reported substantial itch reduction, with 82% of CP patients experiencing marked improvement compared to only 22% in the placebo group. This compelling data highlights not only the efficacy of ATTO-1310 but also the urgent need for effective treatments in a market currently lacking FDA-approved options for chronic pruritus of unknown origin (CPUO).The Science Behind ATTO-1310: An Innovative ApproachWhat sets ATTO-1310 apart is its unique mechanism of action. By specifically targeting the IL-31 ligand, rather than its receptor, this therapy offers a potentially less risky approach, avoiding dermatitis flare-ups associated with receptor blockade. As noted by Dr. Brian Kim, a leading expert in dermatological pharmacology, ATTO-1310 represents a pivotal shift in how we approach itch management and could be a game-changer for chronic conditions that significantly affect quality of life.The Patient Perspective: Relief and HopeChronic itch can be debilitating, often leading to anxiety and depression in those affected. While the science is impressive, the human element cannot be overlooked. Many patients have expressed hope as they participated in this trial; relief from relentless itching offers a pathway to better sleep, improved mental health, and an overall uplift in quality of life. Such trials don't merely test drugs; they change lives.Looking Ahead: Future Developments in TreatmentAs we look to the future, Attovia plans to kick off phase 2 trials, intending to enroll approximately 300 patients in its ATTUNE-CPUO study and 255 in ATTUNE-AD study across 78 sites in North America and Europe. This could potentially revolutionize treatment options within the next few years. Given the growing prevalence of skin conditions, which are increasingly linked to chronic stress and environmental factors, new therapies like ATTO-1310 are crucial.Integrating Beauty and Health: Taking Charge of Skin WellnessSkin health is intimately connected to overall wellness, and advancements such as those seen with ATTO-1310 add to the broader picture of aesthetic medicine trends. Non-invasive treatments focused on skin health are gaining traction, as consumers increasingly recognize the importance of looking good and feeling good. With options ranging from innovative anti-aging solutions to minimally invasive techniques like injectable fillers or laser therapies, the landscape of cosmetic dermatology is evolving.As we bridge the gap between medical treatment and aesthetic improvement, incorporating scientifically-backed skin health advancements into everyday beauty routines can pave the way towards holistic wellness. Understanding the role of collagen production, hyaluronic acid, and RF technology can empower consumers to make informed choices about their skincare regimens.Conclusion: A Call for Awareness and ActionFor those navigating the symptoms of chronic pruritus or atopic dermatitis, the results from the ATTO-1310 study offer not just hope, but a tangible solution on the horizon. As this new treatment approaches potential market availability, staying informed and proactive about skin health becomes paramount. Finding reliable resources, understanding disease management, and consulting with healthcare professionals can be vital steps in reclaiming one's skin and wellness.

Verve Aesthetics Studio

Verve Aesthetics Studio focuses on all things Aesthetic for Upscale Urban Professionals. 

(317) 558-8936

AVAILABLE FROM 8AM - 5PM EST

99 Monon Boulevard, Carmel, IN 46032

ABOUT US

Verve Aesthetics Studio celebrates the people and businesses shaping beauty, aesthetics, and wellness.

© 2026 Verve Aesthetics Studio All Rights Reserved. 99 Monon Boulevard, Carmel, Indiana 46032 . Contact Us . Terms of Service . Privacy Policy

{"company":"Verve Aesthetics Studio","address":"99 Monon Boulevard","city":"Carmel","state":"Indiana","zip":"46032","email":"aeditor@verveaesthetics.studio","tos":"<p>Terms of Service<br />
<br />
Last Updated: September 18, 2026<br />
<br />
Welcome to Verve Aesthetics Studio. These Terms of Service govern your access to and use of the Verve Aesthetics Studio website, content, services, and related materials.&nbsp;<br />
<br />
By accessing or using our website, you agree to these Terms. If you do not agree with any part of these Terms, please do not use the website.<br />
<br />
1. About Verve Aesthetics Studio<br />
Verve Aesthetics Studio is an editorial and media platform focused on documenting and highlighting people, places, businesses, services, and craftsmanship within the aesthetics, beauty, wellness, and related industries.<br />
Verve provides editorial features, articles, business profiles, interviews, promotional materials, and other media content.<br />
Verve is not a medical provider, healthcare provider, medical advice service, or healthcare professional. Content published on this website is intended for general informational and editorial purposes only.<br />
<br />
2. Use of Our Website<br />
You may use the website for lawful purposes and in accordance with these Terms.<br />
You agree not to:<br />
Use the website for any unlawful or fraudulent purpose.<br />
Attempt to gain unauthorized access to our website, systems, or accounts.<br />
Interfere with the operation or security of the website.<br />
Copy, reproduce, distribute, or exploit our content without permission.<br />
Use our content, branding, or materials in a way that suggests an unauthorized partnership or endorsement.<br />
Submit information that is knowingly false, misleading, defamatory, or unlawful.<br />
Upload or transmit malicious software, viruses, or other harmful material.<br />
We reserve the right to restrict or terminate access to the website if we believe these Terms have been violated.<br />
<br />
3. Editorial Content<br />
Verve may publish articles, business profiles, interviews, photographs, videos, quotes, and other editorial materials about businesses, professionals, organizations, and individuals.<br />
Editorial content may be created using information provided by businesses or gathered from publicly available sources.<br />
While we make reasonable efforts to present information accurately, we do not guarantee that every piece of information published on the website is complete, current, or error-free.<br />
Businesses and individuals featured by Verve are responsible for reviewing information they provide to us and notifying us of material inaccuracies.<br />
Publication of a business or individual does not necessarily constitute an endorsement, certification, guarantee, or recommendation by Verve.<br />
<br />
4. Business Features and Submissions<br />
Businesses may be invited to participate in complimentary or paid editorial features.<br />
If you provide information, quotes, photographs, logos, links, or other materials to Verve (&ldquo;Submitted Materials&rdquo;), you represent that:<br />
You have the right to provide the materials to us.<br />
The materials do not knowingly violate another person&#39;s intellectual property or other rights.<br />
The information provided is accurate to the best of your knowledge.<br />
You have permission to provide any photographs, logos, statements, or other materials belonging to your business or organization.<br />
By submitting materials to Verve, you grant Verve permission to use, reproduce, edit, publish, display, and distribute those materials as reasonably necessary to create and promote the requested editorial feature or related content.<br />
<br />
5. Editorial Review and Changes<br />
Verve reserves the right to edit submitted materials for grammar, spelling, formatting, length, clarity, style, and editorial consistency.<br />
We may also decline to publish, modify, update, or remove content at our discretion.<br />
Participation in a feature does not guarantee a particular publication date, placement, audience size, search-engine ranking, social-media reach, traffic level, leads, sales, or other business result.</p>

<p>6. Accuracy of Business Information<br />
Businesses featured on Verve are responsible for ensuring that their business information is accurate.<br />
This may include information such as:<br />
Business name<br />
Address<br />
Phone number<br />
Website<br />
Hours of operation<br />
Services<br />
Pricing<br />
Contact information<br />
Other publicly displayed business details<br />
If you identify an inaccurate or outdated business detail, you may contact Verve to request a correction.<br />
Verve may review correction requests before making changes.<br />
<br />
7. Promotional Features and Press Kits<br />
Verve may offer businesses additional promotional opportunities, including press kits, social-media promotional materials, website placement, editorial visibility, or other promotional services.<br />
Any paid promotional service will be subject to the applicable description, pricing, and terms presented at the time of purchase or agreement.<br />
Payment for a promotional service does not guarantee specific business results, including leads, customers, sales, website traffic, search rankings, or social-media engagement.<br />
<br />
8. Intellectual Property<br />
Unless otherwise stated, the Verve website and its original content, including articles, text, graphics, logos, design elements, photographs, videos, layouts, and branding, are owned by or licensed to Verve and are protected by applicable intellectual property laws.<br />
You may view and access Verve content for personal or informational purposes.<br />
You may not reproduce, republish, modify, distribute, sell, publicly display, or commercially exploit Verve-owned content without prior written permission.<br />
Businesses may share links to their published Verve features for promotional purposes, provided that the content is not altered or presented in a misleading manner.<br />
<br />
9. Third-Party Websites and Services<br />
The Verve website may contain links to third-party websites, platforms, businesses, or services.<br />
These links are provided for convenience and informational purposes. Verve does not control or guarantee the accuracy, availability, security, or policies of third-party websites.<br />
Your use of third-party websites is governed by the terms and policies of those websites.<br />
<br />
10. Health and Wellness Disclaimer<br />
Some Verve content may discuss aesthetics, skincare, beauty, wellness, chiropractic services, cosmetic procedures, or other health-related topics.<br />
Such content is provided for general informational and editorial purposes only and should not be considered medical, professional, diagnostic, or treatment advice.<br />
Verve does not provide medical advice or establish a doctor-patient, provider-patient, or other professional relationship through the website.<br />
Readers should consult an appropriately qualified professional regarding questions about their individual health, treatment, or circumstances.<br />
<br />
11. No Guarantee of Results<br />
Verve does not guarantee that the use of our website, editorial features, promotional services, or published content will result in:<br />
Increased customers or clients<br />
Increased sales or revenue<br />
Increased website traffic<br />
Improved search-engine rankings<br />
Increased social-media engagement<br />
Increased visibility<br />
Leads or appointments<br />
Any particular marketing or business outcome<br />
Results may vary depending on numerous factors outside of Verve&#39;s control.<br />
<br />
12. Disclaimer of Warranties<br />
The website and its content are provided on an &ldquo;as is&rdquo; and &ldquo;as available&rdquo; basis.<br />
To the extent permitted by law, Verve makes no warranties, express or implied, regarding the website&#39;s availability, accuracy, completeness, reliability, or suitability for a particular purpose.<br />
We do not guarantee that the website will always be available, uninterrupted, secure, or free from errors or harmful components.<br />
<br />
13. Limitation of Liability<br />
To the maximum extent permitted by applicable law, Verve and its owners, employees, contractors, contributors, and affiliates will not be liable for indirect, incidental, consequential, special, or other damages arising from or related to your use of the website, reliance on its content, participation in an editorial feature, or use of third-party websites or services.<br />
Nothing in these Terms is intended to exclude or limit liability that cannot legally be excluded or limited under applicable law.<br />
<br />
14. Indemnification<br />
You agree to defend, indemnify, and hold harmless Verve Aesthetics Studio and its owners, employees, contractors, contributors, and affiliates from claims, liabilities, damages, losses, and expenses arising from:<br />
Your violation of these Terms;<br />
Your unlawful use of the website;<br />
Materials you submit to Verve; or<br />
Your violation of another person&#39;s rights.<br />
<br />
15. Privacy<br />
Your use of the website may also be subject to our Privacy Policy, which explains how information submitted through the website may be collected, used, and handled.<br />
<br />
16. Changes to These Terms<br />
We may update these Terms from time to time.<br />
When we make changes, we will update the &ldquo;Last Updated&rdquo; date at the top of this page. Your continued use of the website after changes are posted means that you accept the updated Terms.<br />
<br />
17. Governing Law<br />
These Terms will be governed by and interpreted in accordance with the applicable laws of the jurisdiction in which Verve Aesthetics Studio operates, without regard to conflict-of-law principles.<br />
Any disputes arising from these Terms or your use of the website will be handled in accordance with applicable law.<br />
<br />
18. Contact Us<br />
If you have questions about these Terms, corrections to your business feature, or other concerns regarding the website, please contact us:<br />
<br />
Verve Aesthetics Studio<br />
Email: aeditor@verveaesthetics.studio<br />
Website: verveaesthetics.studio<br />
<br />
By using the Verve Aesthetics Studio website, you acknowledge that you have read, understood, and agreed to these Terms of Service.</p>
","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*